<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921063</url>
  </required_header>
  <id_info>
    <org_study_id>A5361007</org_study_id>
    <nct_id>NCT00921063</nct_id>
  </id_info>
  <brief_title>A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of PD 0332334 compared to
      placebo in the treatment of Generalized Anxiety Disorder in an adult population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAM-A Total Score</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAM-A total score at week 1, 2 and 4</measure>
    <time_frame>1. 2. ands 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A somatic and psychic subscales</measure>
    <time_frame>1, 2, and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A responders</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A sustained responders</measure>
    <time_frame>Week 1 through week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS-A (daily assessment of symptoms of anxiety) and GA-VAS (VAS scale for global anxiety)</measure>
    <time_frame>Day 2 through day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I (Clinical Global Impression of Improvement) and PGI-I (Patient Global Impression of Change)</measure>
    <time_frame>1 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-D total score</measure>
    <time_frame>1 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Score (SDS)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionaire for Medication</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>PD 0332334 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD 0332334 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam extended release</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>250 mg capsule, BID for 4 weeks</description>
    <arm_group_label>PD 0332334 250 mg</arm_group_label>
    <other_name>imagabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>100 mg capsule, BID for 4 weeks</description>
    <arm_group_label>PD 0332334 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0 mg capsule, BID for 4 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam extended release</intervention_name>
    <description>1 mg capsule, BID for 4 weeks</description>
    <arm_group_label>Alprazolam extended release</arm_group_label>
    <other_name>Xanax XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females with a diagnosis of Generalized Anxiety Disorder (GAD)
             (Diagnostic and Statistical Manual-IV [DSM-IV], 300.02).

          -  HAM-A Total Score ≥20 and item #1 on the HAM-D (depressed mood score) ≤2 at both
             Screening and Baseline/Randomization.

        Exclusion Criteria:

          -  Current diagnoses (within the 6 months) of Major Depressive Disorder; Obsessive
             Compulsive Disorder; Panic Disorder; Posttraumatic Stress Disorder; Anorexia; Bulimia;
             Caffeine-induced anxiety disorder;

          -  Any of the following past or current diagnoses: Schizophrenia; Psychotic Disorder;
             Delirium, Dementia, Bipolar or Schizoaffective Disorder; Cyclothymic Disorder;
             Dissociative Disorders; Antisocial or borderline personality disorder

          -  Current use of psychotropic medications (i.e., drugs normally prescribed for
             depression, mania, anxiety, insomnia, or psychosis) that could not be discontinued 2
             weeks prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5361007&amp;StudyName=A%205-Week%20Trial%20Of%20PD%200332334%20And%20Alprazolam%20Extended%20Release%20Compared%20To%20Placebo%20In%20Patients%20With%20Generalized%20Anxiety%20Disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>February 17, 2010</last_update_submitted>
  <last_update_submitted_qc>February 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

